SciClone Pharmaceuticals Inc. (NASDAQ:SCLN) was down 20.6% during trading on Tuesday . The stock traded as low as $10.25 and last traded at $10.53, with a volume of 953,768 shares trading hands. The stock had previously closed at $13.26.

The stock has a market capitalization of $524.04 million and a P/E ratio of 19.44. The company’s 50 day moving average is $13.59 and its 200-day moving average is $11.23.

SciClone Pharmaceuticals (NASDAQ:SCLN) last issued its quarterly earnings results on Tuesday, May 10th. The specialty pharmaceutical company reported $0.19 earnings per share (EPS) for the quarter. The company earned $36.50 million during the quarter, compared to the consensus estimate of $33.60 million. Equities analysts predict that SciClone Pharmaceuticals Inc. will post $0.33 earnings per share for the current fiscal year.

Several large investors recently modified their holdings of the stock. Dimensional Fund Advisors LP boosted its stake in shares of SciClone Pharmaceuticals by 2.2% in the fourth quarter. Dimensional Fund Advisors LP now owns 2,559,182 shares of the specialty pharmaceutical company’s stock valued at $23,544,000 after buying an additional 53,987 shares during the period. Matarin Capital Management LLC bought a new stake in shares of SciClone Pharmaceuticals during the fourth quarter valued at about $1,600,000. Cornerstone Capital Management Holdings LLC. boosted its stake in shares of SciClone Pharmaceuticals by 32.3% in the fourth quarter. Cornerstone Capital Management Holdings LLC. now owns 198,570 shares of the specialty pharmaceutical company’s stock valued at $1,827,000 after buying an additional 48,470 shares during the period. Finally, GSA Capital Partners LLP boosted its stake in shares of SciClone Pharmaceuticals by 20.0% in the fourth quarter. GSA Capital Partners LLP now owns 325,115 shares of the specialty pharmaceutical company’s stock valued at $2,991,000 after buying an additional 54,227 shares during the period.

SciClone Pharmaceuticals, Inc is a pharmaceutical company. The Company’s product portfolio of therapies includes oncology, infectious diseases and cardiovascular disorders. The Company operates in two segments: China and the Rest of the World, including its operations in the United States and Hong Kong.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.